Xencor, Inc.
IL-15/IL-15RA HETERODIMERIC FC FUSION PROTEINS AND USES THEREOF
Last updated:
Abstract:
The present invention is directed to novel IL-15/IL-15R.alpha. heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R.alpha. heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R.alpha. heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
Status:
Application
Type:
Utility
Filling date:
22 Mar 2021
Issue date:
10 Feb 2022